Email:
global@GCP-ClinPlus.com
July 22 marks World Brain Day. The 2026 theme, “Brain Health: Access for All,” highlights the persistent global disparities in access to brain health care.
According to the World Federation of Neurology (WFN), more than 3.4 billion people—over 40% of the global population—are living with neurological conditions. Brain disorders are now the leading cause of disability worldwide.
In many regions, there is less than one neurologist per million people. In under-resourced communities, patients may wait up to five years between symptom onset and a formal diagnosis by a specialist.
Access delayed is potentially access denied.
Closing the brain health gap requires earlier diagnosis, stronger health care capacity, more equitable access to services, and continued clinical research innovation.
Across Alzheimer’s disease, Parkinson’s disease, stroke, and other neurological conditions, clinical trials help deepen our understanding of disease mechanisms, evaluate the safety and efficacy of new therapies, and explore new treatment possibilities for patients.
With 23 years of clinical research experience, GCP ClinPlus has conducted more than 50 studies across neurology and central nervous system indications, including Alzheimer’s disease, Parkinson’s disease, and ALS. We also continue to build experience in innovative modalities such as oligonucleotide therapeutics and gene therapies.
On World Brain Day, we extend our support to everyone affected by neurological conditions and our respect to the researchers, clinicians, and clinical research professionals working to advance brain health.
Brain health belongs to everyone.
global@gcp-clinplus.com
#WorldBrainDay #BrainHealth #NeurologicalDisorders #ClinicalTrials #Neuroscience #CRO #GCPClinPlus